Tax First-line Chemotherapy With Different Doses and Then Maintenance Therapy
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The Primary Objective is to evaluate the progression-free survival (PFS).
The secondary objectives are:
- To compare the disease control rates of different doses of Docetaxel+Cisplatin as
first-line treatment according to Response Evaluation Criteria In Solid Tumors (RECIST)
criteria;
- To evaluate the overall response rate (ORR);
- To evaluate the time to disease progression (TTP);
- To evaluate the overall survival (OS);
- To evaluate the toxicity.